Major DepressionPhase 4NCT04093960
Escitalopram Plus PS128 vs. Escitalopram
A Phase 4 study testing Lactobacillus plantarum PS128 in people with Major Depression, run by Kaohsiung Kai-Suan Psychiatric Hospital at 1 site in Taiwan.
Trial summary
The purpose of this study is to compare the efficacy and safety of escitalopram plus PS128 to escitalopram in the acute treatment of patients with major depressive disorder. Read more about this study
- Who is it for?
- Ages 20 to 65 years
- Conditions the study is for
- Major Depression
- What is being tested?
- Lactobacillus plantarum PS128
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 41 participants
- Where
- 1 siteTaiwan
- Study dates
- 18 Nov 2016to 1 Sep 2019
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Major depressive disorder
- CGI >=4
- the score of the 17-item Hamilton Rating Scale for Depression (HAMD-17) was 18 or higher.
- washout of antipsychotics at least 3 days
- written informed consents
- Not taking fluoxetine at least one month before admission.
Who cannot join
- History of schizophrenia, schizoaffective disorder or organic mental disorders.
- comorbid with substance abuse/dependence in the past 6 months.
- with psychotic features
- treatment-resistant depression or receiving electroconvulsive therapy.
- History of serious adverse events to escitalopram
- female subjects with pregnancy or lactation.
Show all 9Show fewer
- severe physical illness
- receiving antibiotics treatment in the past two weeks.
- taking products with probiotics.
Trial locations and contacts
1 site in 1 country.
Taiwan1 site
Kaohsiung Municipal Kai-Syuan Psychiatric Hospital
Kaohsiung City, 886
About this study
Official title: A Randomized, Double-blind, Comparison of the Efficacy and Safety of Escitalopram Plus PS128 to Escitalopram in the Acute Treatment of Patients With Major Depressive Disorder
The purpose of this study is to compare the efficacy and safety of escitalopram plus PS128 to escitalopram in the acute treatment of patients with major depressive disorder.
Read the detailed description
In this 6-week, double-blind, fixed-dose study, patients with major depressive disorder are randomly assigned to escitalopram (10 mg daily) plus PS128 (a psychobiotic) (300 mg two times daily, equivalent to 3 ×1010 CFU two times daily) or escitalopram (10 mg daily) groups. The rating scales and instrument, including Clinical Global Impression-Severity, 17-item Hamilton Rating Scale for Depression, Hamilton Anxiety Rating Scale, Global Assessment of Functioning, Heart Rate Variability, Depression and Somatic Symptoms Scale, Work and Social Adjustment Scale, Short form 36 and Pittsburgh Sleep Quality Index, are used to measure treatment outcomes at weeks 0, 1, 2, 3, 4, 5, and 6. UKU Side Effect Rating Scale and Gastrointestinal Symptom Rating Scale-Irritable Bowel Syndrome are used to measure side effects. Generalized estimating equations model will be used to analyze the differences between two groups with respect to efficacy and safety measures on time after adjusting for baseline severity, sex, age and age at onset of illness.
- Conditions
- Major Depression
- Being tested
- Lactobacillus plantarum PS128
- Keywords
- psychobiotics, major depressive disorder, escitalopram
- Medical subject headings
- Depressive Disorder, Major
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Lactobacillus plantarum PS128Dietary supplement
10 mg qd of escitalopram qd plus 300mg bid of Lactobacillus plantarum PS128 to enhance antidepressive effect
| Study group | Role | What they receive |
|---|---|---|
| escitalopram plus128 | Experimental | escitalopram (10 mg daily) plus PS128(a psychobiotic) (300 mg two times daily, equivalent to 3 ×1010 CFU two times daily) Receives: Dietary Supplement: Lactobacillus plantarum PS128 |
| escitalopram | Active comparator | 10 mg/d of escitalopram Receives: Dietary Supplement: Lactobacillus plantarum PS128 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Depression severity by the change of 17-item Hamilton Rating Scale for Depression (HAMD-17) total scores
17-item Hamilton Rating Scale for Depression (HAMD-17) is widely used in clinical setting to evaluate depression symptoms in the past week. Higher total HAMD-17 scores (ranging from 0 to 52) indicate more severe depression.
Measured: Time Frame: The HAMD-17 was rated at baseline, and again at weeks 1, 2, 3, 4, 5 and 6 (or on early termination).
Secondary outcomes (18)
Clinical severity by Clinical Global Impression-Severity (CGI-S)
The CGI was developed for use in NIMH-sponsored clinical trials to provide a brief, stand-alone assessment of the clinician's view of the patient's global functioning prior to and after initiating a study medication. The CGI comprises one-item measures evaluating the severity of psychopathology from 1 to 7 and higher scores indicate higher severity.
Measured: The scales were rated at baseline, and again at weeks 1, 2, 3, 4, 5 and 6 (or on early termination).
Assessments of safety for general adverse events
General adverse events were evaluated by a standardized the UKU Side Effect Rating Scale. A score of 1, 2 or 3 on any UKU item that first occurred or worsened during treatment indicated adverse events "cases".
Measured: The scales were rated at baseline, and again at weeks 1, 2, 3, 4, 5 and 6 (or on early termination).
Change of body weights
Body weights
Measured: Time Frame: Body weights were assessed at baseline and week 6(or on early termination).
Change of body mass index (BMI)
body mass index (BMI)
Measured: Time Frame: BMI was assessed at baseline and week 6(or on early termination).
Change of pulse rate
pulse rate
Measured: Time Frame: Pulse rates were checked at baseline and at weeks 1, 2, 3, 4, and 6 (or on early termination).
Change of blood pressure
blood pressure (both systolic and diastolic)
Measured: Time Frame: Blood pressure were checked at baseline and at weeks 1, 2, 3, 4, and 6 (or on early termination).
Change of ECG QT Interval
12-lead electrocardiogram (ECG) ECG QT Interval.
Measured: Time Frame: ECG were assessed at baseline and week 6 (or on early termination).
change of fasting glucose.
Laboratory tests including fasting glucose.
Measured: Time Frame: laboratory test mentioned above were assessed at baseline and week 6(or on early termination.
change of liver function
Laboratory tests including alanine aminotransferase [ALT] and aspartate aminotransferase [AST].
Measured: Time Frame: laboratory test mentioned above were assessed at baseline and week 6 (or on early termination).
change of renal function
Laboratory tests including blood urea nitrogen [BUN], creatinine.
Measured: Time Frame: laboratory test mentioned above were assessed at baseline and week 6 (or on early termination).
change of lipid profiles.
Laboratory tests including triglycerides, cholesterol, high density lipoprotein [HDL], and low density lipoprotein [LDL].
Measured: Time Frame: laboratory test mentioned above were assessed at baseline and week 6(or on early termination).
Assessments of quality of life
The Short-Form-36 (SF-36) is comprised of the physical component summary (PCS) which measures physical health, and the mental component summary (MCS) which measures mental health. PCS includes 4 subscales: 1) physical functioning, 2) role physical limitations, 3) body pain, 4) general health; MCS includes 4 subscales: 1) vitality, 2) social functioning, 3) role emotional limitations, and 4) mental health. SF-36 raw scores were processed according to the user manual to obtain standardized scores for all 8 SF-36 subscales, PCS and MCS. Scores for the SF-36 subscales range from 0 to 100, with a higher score representing better QOL. The PCS and MCS were standardized according to general population means and variances to produce scores with a common mean of 50 and standard deviation of 10 (T-scores). Thus, any score < 50 represents a reduction from "normal" health.
Measured: Time Frame: Medical Outcomes Study Short-Form 36 was assessed at baseline and week 6
Assessments of heart rate variability
Heart rate variability
Measured: Time Frame: Heart rate variability was assessed at baseline and week 6
depression and somatic symptoms evaluation
The Depression and Somatic Symptoms Scale (DSSS) is composed of a 12-item depression subscale (DS) and a ten-item somatic subscale (SS), which includes a five-item pain subscale (PS). Each item is scored from 0 to 3 (absent, mild, moderate, and severe) according to the severity of symptoms, with the total score ranging from 0 to 36 and 0-30 for the DS and the SS, respectively. Higher total score indicates more severe depression and somatic symptoms.
Measured: The scales were rated at baseline, and again at weeks 1, 2, 3, 4, 5 and 6 (or on early termination).
Gastrointestinal Symptoms evaluation
Gastrointestinal Symptom Rating Scale-Irritable Bowel Syndrome (GSRS) includes 15 questions on a scale of 1 to 7, depending on how inconvenient it had been during the previous week. A higher score indicates more inconvenient symptoms. Combination scores among 15 questions can assess the following five domains: reflux syndrome (heartburn and acid regurgitation), abdominal pain (stomach ache, gastric hunger pains and nausea), indigestion syndrome (gastric borborygmus, gastric bloating, eructation and increased flatus), diarrhea syndrome (diarrhea, loose stools and urgent need to defecate) and constipation syndrome (constipation, hard stools and feeling of incomplete evacuation).
Measured: The scales were rated at baseline, and again at weeks 1, 2, 3, 4, 5 and 6 (or on early termination).
Sleep Quality evaluation: The Pittsburgh Sleep Quality Index (PSQI)
The Pittsburgh Sleep Quality Index (PSQI) is a 19-item, self-rated questionnaire designed to measure sleep quality and disturbance over the past month in clinical populations. The 19 items are grouped into 7 components, including (1) sleep duration, (2) sleep disturbance, (3) sleep latency, (4) daytime dysfunction due to sleepiness, (5) sleep efficiency, (6) overall sleep quality, and (7) sleep medication use. Each of the sleep components yields a score ranging from 0 to 3, with 3 indicating the greatest dysfunction. The sleep component scores are summed to yield a total score ranging from 0 to 21 with the higher total score (referred to as global score) indicating worse sleep quality. In distinguishing good and poor sleepers, a global PSQI score > 5 yields a sensitivity of 89.6% and a specificity of 86.5%.
Measured: The scales were rated at baseline, and again at weeks 1, 2, 3, 4, 5 and 6 (or on early termination).
Function evaluation
Global Assessment of Functioning (GAF) is used to rate severity of illness in psychiatry and covers the range from positive mental health to severe psychopathology. It is an overall (global) measure of how patients are doing Internationally, recording GAF is either done with a single value (this is the most severe of the symptom and functioning values) or both symptom (GAF-S) and functioning (GAF-F) values are recorded. The symptom and functioning scales have both 100 scoring possibilities (1-100). The 100-point scales are divided into 10 intervals, or sections, each with 10 scoring possibilities (examples: 31-40 and 51- 60). Verbal instructions (called anchor points) describe symptoms and functioning relevant for scoring in the 10-point intervals.
Measured: The scales were rated at baseline, and again at weeks 1, 2, 3, 4, 5 and 6 (or on early termination).
change of work and social adjustment
Work and Social Adjustment Scale(WSAS) is a widely used questionnaire by patients' perspectives concerning impaired functioning. The WSAS comprises 5 items (work, home management, social leisure, private leisure, and relationships; see Appendix A), each rated on a scale of 0 to 8, which can also be pooled (total score 0-40; higher scores denote more disability)
Measured: The scales were rated at baseline, and again at weeks 1, 2, 3, 4, 5 and 6 (or on early termination).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Sep 2019
- Study start18 Nov 2016
- Primary completion4 Mar 2019
- Study completion1 Sep 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Major DepressionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 41 participants (actual)
Sponsor and investigators
- Lead sponsor
- Kaohsiung Kai-Suan Psychiatric Hospital
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Ching-Hua Lin, MD, PhD, Kaohsiung Kai-Suan Psychiatric Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04093960
- Sponsor's protocol ID
- KSPH-2016-02
- Status last verified
- Sep 2019
- First submitted
- 2 Sep 2019
- Last updated
- 18 Sep 2019
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 18 Sep 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-blind, Comparison of the Efficacy and Safety of Escitalopram Plus PS128 to Escitalopram in the Acute Treatment of Patients With Major Depressive Disorder
- ClinicalTrials.gov ID
- NCT04093960
- Acronym / sponsor ID
- KSPH-2016-02
- Conditions
- Major Depression
- Keywords
- psychobiotics, major depressive disorder, escitalopram
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Terminated
- Enrolment
- 41 participants (actual)
- Lead sponsor
- Kaohsiung Kai-Suan Psychiatric HospitalOther government
- Study start
- 18 Nov 2016 (actual)
- Primary completion
- 4 Mar 2019 (actual)
- Study completion
- 1 Sep 2019 (actual)
- First posted
- 18 Sep 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to compare the efficacy and safety of escitalopram plus PS128 to escitalopram in the acute treatment of patients with major depressive disorder.
Detailed description
In this 6-week, double-blind, fixed-dose study, patients with major depressive disorder are randomly assigned to escitalopram (10 mg daily) plus PS128 (a psychobiotic) (300 mg two times daily, equivalent to 3 ×1010 CFU two times daily) or escitalopram (10 mg daily) groups. The rating scales and instrument, including Clinical Global Impression-Severity, 17-item Hamilton Rating Scale for Depression, Hamilton Anxiety Rating Scale, Global Assessment of Functioning, Heart Rate Variability, Depression and Somatic Symptoms Scale, Work and Social Adjustment Scale, Short form 36 and Pittsburgh Sleep Quality Index, are used to measure treatment outcomes at weeks 0, 1, 2, 3, 4, 5, and 6. UKU Side Effect Rating Scale and Gastrointestinal Symptom Rating Scale-Irritable Bowel Syndrome are used to measure side effects. Generalized estimating equations model will be used to analyze the differences between two groups with respect to efficacy and safety measures on time after adjusting for baseline severity, sex, age and age at onset of illness.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| escitalopram plus128 | Experimental | Dietary Supplement: Lactobacillus plantarum PS128escitalopram (10 mg daily) plus PS128(a psychobiotic) (300 mg two times daily, equivalent to 3 ×1010 CFU two times daily) |
| escitalopram | Active comparator | Dietary Supplement: Lactobacillus plantarum PS12810 mg/d of escitalopram |
Who may qualify
- Ages
- 20 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Major depressive disorder
- CGI >=4
- the score of the 17-item Hamilton Rating Scale for Depression (HAMD-17) was 18 or higher.
- washout of antipsychotics at least 3 days
- written informed consents
Key exclusion criteria (9 listed)
- History of schizophrenia, schizoaffective disorder or organic mental disorders.
- comorbid with substance abuse/dependence in the past 6 months.
- with psychotic features
- treatment-resistant depression or receiving electroconvulsive therapy.
- History of serious adverse events to escitalopram
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Lactobacillus plantarum PS12810 mg qd of escitalopram qd plus 300mg bid of Lactobacillus plantarum PS128 to enhance antidepressive effect | Dietary supplement | escitalopram, escitalopram plus128 |
Primary outcome
Depression severity by the change of 17-item Hamilton Rating Scale for Depression (HAMD-17) total scores
Time frame: Time Frame: The HAMD-17 was rated at baseline, and again at weeks 1, 2, 3, 4, 5 and 6 (or on early termination).
17-item Hamilton Rating Scale for Depression (HAMD-17) is widely used in clinical setting to evaluate depression symptoms in the past week. Higher total HAMD-17 scores (ranging from 0 to 52) indicate more severe depression.
18 secondary outcomes
Clinical severity by Clinical Global Impression-Severity (CGI-S)
Time frame: The scales were rated at baseline, and again at weeks 1, 2, 3, 4, 5 and 6 (or on early termination).
Assessments of safety for general adverse events
Time frame: The scales were rated at baseline, and again at weeks 1, 2, 3, 4, 5 and 6 (or on early termination).
Change of body weights
Time frame: Time Frame: Body weights were assessed at baseline and week 6(or on early termination).
Change of body mass index (BMI)
Time frame: Time Frame: BMI was assessed at baseline and week 6(or on early termination).
Change of pulse rate
Time frame: Time Frame: Pulse rates were checked at baseline and at weeks 1, 2, 3, 4, and 6 (or on early termination).
Change of blood pressure
Time frame: Time Frame: Blood pressure were checked at baseline and at weeks 1, 2, 3, 4, and 6 (or on early termination).
Change of ECG QT Interval
Time frame: Time Frame: ECG were assessed at baseline and week 6 (or on early termination).
change of fasting glucose.
Time frame: Time Frame: laboratory test mentioned above were assessed at baseline and week 6(or on early termination.
change of liver function
Time frame: Time Frame: laboratory test mentioned above were assessed at baseline and week 6 (or on early termination).
change of renal function
Time frame: Time Frame: laboratory test mentioned above were assessed at baseline and week 6 (or on early termination).
change of lipid profiles.
Time frame: Time Frame: laboratory test mentioned above were assessed at baseline and week 6(or on early termination).
Assessments of quality of life
Time frame: Time Frame: Medical Outcomes Study Short-Form 36 was assessed at baseline and week 6
Assessments of heart rate variability
Time frame: Time Frame: Heart rate variability was assessed at baseline and week 6
depression and somatic symptoms evaluation
Time frame: The scales were rated at baseline, and again at weeks 1, 2, 3, 4, 5 and 6 (or on early termination).
Gastrointestinal Symptoms evaluation
Time frame: The scales were rated at baseline, and again at weeks 1, 2, 3, 4, 5 and 6 (or on early termination).
Sleep Quality evaluation: The Pittsburgh Sleep Quality Index (PSQI)
Time frame: The scales were rated at baseline, and again at weeks 1, 2, 3, 4, 5 and 6 (or on early termination).
Function evaluation
Time frame: The scales were rated at baseline, and again at weeks 1, 2, 3, 4, 5 and 6 (or on early termination).
change of work and social adjustment
Time frame: The scales were rated at baseline, and again at weeks 1, 2, 3, 4, 5 and 6 (or on early termination).
Results and safety
The study was stopped early. Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Sep 2019.
- Individual participant dataSharing planned: Undecided
Related trials for Major Depression
RecruitingPhase 3
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
Depressive Disorder, Major
Recruiting
EEG-Guided Transcranial Magnetic Stimulation for Adults With Depression
Major Depressive Disorder (MDD), Treatment Resistant Depression
Recruiting
Defining Neurobiological Links Between Substance Use and Mental Illness
Major Depressive Disorder, Substance Use Disorder
RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
Depressive Disorder, Major
RecruitingPhase 3
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
Bipolar Depression
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Lactobacillus plantarum PS128 in people with Major Depression, run by Kaohsiung Kai-Suan Psychiatric Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 18 Sep 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early. Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Depression severity by the change of 17-item Hamilton Rating Scale for Depression (HAMD-17) total scores (time frame: Time Frame: The HAMD-17 was rated at baseline, and again at weeks 1, 2, 3, 4, 5 and 6 (or on early termination).). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Sep 2019.